Clinical Trial Update: Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial (Tokio Study) evaluating a third-line tyrosine kinase inhibitor after two prior TKIs in metastatic renal cell carcinoma; the study status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Renal Cancer Cell | Phase 2 | Status: TERMINATED